Diflucan 150 mg (Fluconazole) and Pimozide: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Pimozide combined with an established systemic QT-prolonging medicine presents a serious arrhythmia risk. Systemic CYP3A inhibition can increase pimozide exposure and its QT-related arrhythmia risk.
Clinical significance and safety
Diflucan 150 mg (Fluconazole) and Pimozide: Pimozide combined with an established systemic QT-prolonging medicine presents a serious arrhythmia risk. Systemic CYP3A inhibition can increase pimozide exposure and its QT-related arrhythmia risk. This combination is contraindicated under the cited pimozide product information for established QT-prolonging partners. It needs prompt prescriber or pharmacist review, not self-directed dose changes. Heart disease, a slow pulse and low potassium or magnesium can increase concern. A clinician determines whether ECG or electrolyte checks are needed. Fainting or new irregular palpitations require urgent assessment. Changes in exposure can affect tolerability or treatment response. The prescriber must check the exact inhibitor, formulation, dose and timing against the cited product information; doses should not be adjusted without that review.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.